In human anatomy, the acromion (from Greek: akros, "highest", ōmos, "shoulder", plural: acromia) is a bony process on the scapula (shoulder blade). Together with the coracoid process it extends laterally over the shoulder joint. The acromion is a continuation of the scapular spine, and hooks over anteriorly. It articulates with the clavicle (collar bone) to form the acromioclavicular joint. Structure
The acromion forms the summit of the shoulder, and is a large, somewhat triangular or oblong process, flattened from behind forward, projecting at first lateralward, and then curving forward and upward, so as to overhang the glenoid fossa. It starts from the base of acromion which marks its projecting point emerging from the spine of scapula. Surfaces
Its superior surface, directed upward, backward, and lateralward, is convex, rough, and gives attachment to some fibers of the deltoideus, and in the rest of its extent is subcutaneous. Its inferior surface is smooth and concave. Borders
Its lateral border is thick and irregular, and presents three or four tubercles for the tendinous origins of the deltoid. Its medial border, shorter than the lateral, is concave, gives attachment to a portion of the trapezius, and presents about its center a small oval surface for articulation with the acromial end of the clavicle. Variation
There are three morphologically distinct types of acromia and a correlation between these morphologies and rotator cuff tear:

Os acromiale
The acromion has four ossification centers called (from tip to base) pre-acromion, meso-acromion, meta-acromion, and basi-acromion.
An increase of the QT interval of more than 60 ms was detected in 1.2% of people receiving etelcalcetide.Due to the lower iPTH levels achieved by the use of this drug, it is possible that adynamic bone disease could occur at levels "below 100 pg/mL"

Contraindications
The drug is contraindicated in people with blood serum calcium levels below the norm. Chemistry
The substance is a peptide consisting mostly of D-amino acids instead of the common L-amino acids. More specifically, it is the disulfide of N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide with L-cysteine. History
Originally, Etelcalcetide was being developed by KAI Pharmaceuticals. After positive Phase II trials, Amgen acquired KAI for $315 Million.In 2011, KAI entered into agreement with Ono Pharmaceutical for production of Etelcalcetide in Japan, the deal being worth ¥1 Billion.On 25 August 2015 Amgen Inc. announced its submission of a new drug application to the Food and Drug Administration for etelcalcetide. The European Medicines Agency approved the drug in November 2016.In February 2017, the FDA approved Parsabiv for the treatment of secondary hyperparathyroidism. Research
Phase II trials found that Etelcalcetide was able to lower PTH levels in one cohort by -49% vs a 29% increase in the placebo group. In another Phase II study "89% of patients experienced a C30% reduction in PTH and 56% achieved a PTH level of B300 pg/mL. "In 2017, two Phase III trials found that using etelcalcetide showed greater symptom reduction compared to placebo. Etelcalcetide was also able to lower PTH levels below 300pg/mL more often.Phase I Pediatric studies are planned for the US and UK for etelcalcetide.